Headerbild

State-of-the-art research

Smart bacteria

Evidence-based therapies

State-of-the-art research

Smart bacteria

Evidence-based therapies

Synformulas Logo
Synformulas is a leading global probiotics company with a focus on smart bacteria for treating patients with allergies and gastrointestinal diseases.

A breakthrough in the treatment of irritable bowel syndrome has already been achieved: In two independent studies, the bacterial strain MIMBb75 displayed a significant effect with regard to the widespread disease irritable bowel syndrome; in addition, it is now the most widely used bacterial strain in Europe for this indication.

To develop future-oriented products with clinically proven efficacy, Synformulas employs an efficient team for research & development and cooperates with a broad network of internationally recognised researchers and universities.

  • Arbeitgeber einer neuen Generation dynamischer Talente

  • Inkubator globaler Trends und Innovationen in Healthcare

  • Accelarator mit nationalen und internationalen Strukturen

VISION

Our vision is to make a decisive contribution to improving the quality of life by researching the complex relationships between health and the human microbiome. To this end, we develop evidence-based therapies with patented bacterial strains.

As an employer of a new dynamic generation, we always have the courage to take unusual paths. We think big and put our visions into practice as quickly as possible.
Our goals:
• take a pioneering role in microbiome research
• make a decisive contribution to improving the quality of life

PRODUCTS

Synformulas GmbH focuses on innovative OTC-preparations with scientifically proven effects. The product portfolio under the Kijimea® brand includes probiotics, medical products, and enzyme preparations.

Kijimea Reizdarm Pro EN

Kijimea Reizdarm Pro EN

What is Kijimea IBS PRO?

Kijimea® IBS PRO is the development of the medical device Kijimea® IBS. With the patch effect of the heat-inactivated bifidobacterial strain B. bifidum HI-MIMBb75, Kijimea® IBS PRO combats all intestinal complaints of IBS such as diarrhoea, abdominal pain, flatulence, or constipation even more effectively. Its significant effectiveness was proven in a clinical study and was recently published in The Lancet, Andresen V. et al. 2020.
Kijimea® IBS PRO does not contain preservatives, sweeteners, flavourings, lactose or gluten and is also ideal for patients with diabetes. Kijimea® IBS also contains no gelatine and is vegan.

 

Find out more about the product.

Regularis EN

Regularis EN

What is Kijimea® Regularis?

Kijimea® Regularis contains the unique Synformularis2 fibre complex. Thanks to its special structure, it is activated by water within a few seconds, but only swells in the intestine.
This gently stretches the intestinal muscles. It receives an impulse to move normally again. The food in the intestine is naturally transported further. The intestine regains its momentum on its own.
Kijimea® Regularis also reduces the surface tension of the gases. These decompose and dissolve naturally - the bloated belly disappears.

Find out more about the product.

Kijimea Synpro 20 EN

Kijimea Synpro 20 EN

What is Kijimea® Synpro 20?

Kijimea® Synpro 20 is a dietary supplement containing 20 selected microcultures that occur in the natural intestinal flora of humans. In addition, Kijimea® Synpro 20 contains choline, FOS, inulin and biotin, which helps to maintain normal mucous membranes.

Find out more about the product.

Kijimea Immun EN

Kijimea Immun EN

What is Kijimea Immun?

Kijimea® Immune contains the three highly specific microculture strains Lactobacillus plantarum LP 02, Lactobacillus rhamnosus LR 04 and Bifidobacterium lactis BS 01. It also contains FOS, choline, riboflavin as well as vitamin D and biotin.
Kijimea® Immun contains no preservatives, sweeteners or flavourings and is also optimally suited for patients with diabetes. As Kijimea® Immun does not contain lactose, it is well tolerated by patients with lactose intolerance. It is not suitable for people with fructose intolerance due to the prebiotic FOS (fructo-oligo-saccharides) it contains.

 

Find out more about the product.

Kijimea Derma EN

Kijimea Derma EN

What is Kijimea® Derma?

The dietary supplement Kijimea® Derma was specially developed to support the skin from inside. It contains the unique microculture L. salivarius FG01, choline and the vitamins riboflavin and biotin.
Kijimea® Derma contains no preservatives, sweeteners, flavourings, lactose or gluten and is also ideal for patients with diabetes.

 

Find out more about the product.

Kijimea Basis 10 EN

Kijimea Basis 10 EN

What is Kijimea® Basis 10?

In extensive research, our experts have developed a special, unique combination of 10 selected microcultures, which occur naturally in a healthy intestinal flora and can thus support intestinal health.
Kijimea® Basis 10 does not contain any preservatives, sweeteners or flavourings and is suitable for patients with diabetes. It does not contain lactose and is 10 is gluten-free.

 

Find out more about the product.

MILESTONES

2011
Launch of the blockbuster Kijimea® Irritable Bowel Syndrome
Study publication on the bifidobacterial strain exclusively contained in Kijimea® Irritable Bowel Syndrome
2015
Kijimea® Irritable Bowel is Product of the Year1
2017
Product launch Kijimea® Synpro 20
2018
Kijimea® Irritable Bowel was certified as "Highest Efficacy"2
Product launch Kijimea® Regularis
2019
Further development of the market leader Kijimea® Irritable Bowel to Kijimea® Irritable Bowel PRO
Product launch of Kijimea® K 53 and Kijimea® Irritable Stomach
2020
Publication of the world's largest OTC irritable bowel study, The Lancet Gastroenterology and Hepatology
 

Über uns – Synformulas GmbH

Become part of the FUTRUE family.
Become part of the FUTRUE family.

1 Online consumer survey in Germany in the period 13.05. - 06.07.2015, conducted by Q&A Research BV. A total of 4,522 ratings in 17 categories. Kijimea® Irritable Bowel was voted first place in the health category.

2 Kijimea® Irritable Bowel was awarded the rating "very good" for efficacy and tolerability in the category Stomach & Intestine a major German test. (Focus 23/18 v. 2.6.2018)